Back to Search
Start Over
Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors
- Source :
- Journal of Clinical Oncology. 28:e13091-e13091
- Publication Year :
- 2010
- Publisher :
- American Society of Clinical Oncology (ASCO), 2010.
-
Abstract
- e13091 Background: NGR-hTNF is a vascular targeting agent exploiting a tumor homing peptide (NGR) that selectively binds an aminopeptidase N overexpressed on tumor blood vessels. Previously, a phas...
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 28
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........d4c3a7654da945a5ba95059b9b3f268b